Collplant Biotechnologies

CLGN · NASDAQ

$3.88+$0.00 (+0.00%)TodayMarket closed · Oct 21, 4:01 AM ET

Prev close $3.88

CLGN analyst rating

HoldConsensus of 1 analyst over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold1
Underperform0
Sell0

12-month price target · 3 analysts

Average $11.22 (+189.2% upside)

Low: $11.11
Now: $3.88
High: $11.55

Upgrades and downgrades

The latest rating actions, newest first

CLGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
D. Boral Capital	Feb 6, 2026	Downgrade	Buy → Hold	—	29%
D. Boral Capital	Nov 28, 2025	Maintains	Buy	$12.00	29%

The case for and against

Updated May 19, 2026

Bull case

CollPlant Biotechnologies is facing a challenging capital environment with a recent $2.0M registered direct financing, leading the financial analyst to lower the stock rating from Buy to Hold. However, the company's partnership with AbbVie for their dermal filler and the potential for positive data or regulatory advances for their own regenerative candidates provide potential catalysts for improved market outlook and cashflow. Despite de minimis revenues and a reduction in operating expenses, CollPlant holds a solid cash balance of $8.5M as of September 30, 2025.

Bear case

CollPlant Biotechnologies is highly reliant on its partnership with AbbVie to develop and commercialize its proprietary rhCollagen product, posing a significant risk if the collaboration is unsuccessful or does not result in high demand for its products. The company also faces significant risks in clinical and regulatory processes, competition in the market, and potential legal and intellectual property issues, which could hinder its growth and profitability. Additionally, decreasing revenues and a tight cost base signal potential financial difficulties in the near-term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.